Table 4.
Subgroup analysis of patients with ER ≥ 10% expression (n = 1952)
| TTR |
OS |
|||
|---|---|---|---|---|
| Variable | HR (95% CI) | P value | HR (95% CI) | P value |
| Age | 0.974 (0.965–0.983) | <0.001 | – | – |
| BMI | – | – | 1.02 (1.01–1.04) | 0.01 |
| Race | ||||
| White | (reference) | (reference) | ||
| Black | 1.00 (0.75–1.34) | 0.98 | – | – |
| Hispanic | 0.74 (0.56–0.98) | 0.03 | – | – |
| Asian/Others | 1.03 (0.70–1.52) | 0.87 | – | – |
| Nuclear grade | – | – | (reference) | |
| III | – | – | 0.77 (0.6–0.98) | 0.03 |
| I/II | ||||
| Histology | ||||
| Ductal | – | – | (reference) | |
| Lobular | – | – | 0.78 (0.52–1.16) | 0.22 |
| Others | – | – | 0.57 (0.37–0.89) | 0.01 |
| Clinical stage | ||||
| Stage III | (reference) | (reference) | ||
| Stage II | 0.51 (0.42–0.62) | <0.001 | 0.51 (0.4–0.65) | <0.001 |
| PR, categorical | ||||
| PR ≥ 10% | (reference) | (reference) | ||
| PR < 1% | 1.77 (1.39–2.24) | <0.001 | 1.80 (1.36–2.36) | <0.001 |
| 1% ≤ PR < 10% | 1.34 (1.01–1.76) | 0.04 | 1.44 (1.03–2.00) | 0.03 |
| Pathological response | ||||
| pCR | (reference) | (reference) | ||
| Non-pCR | 3.31 (1.75–6.25) | <0.001 | 5.61 (2.07–15.16) | <0.001 |
| LVI | ||||
| Negative | (reference) | (reference) | ||
| Positive | 1.72 (1.42–2.10) | <0.001 | 1.68 (1.32–2.13) | <0.001 |
| Neoadjuvant regimens | ||||
| A+T | (reference) | – | – | |
| A | 1.17 (0.90–1.51) | 0.24 | – | – |
| T | 1.93 (1.27–2.93) | 0.002 | – | – |
| Adjuvant hormonal therapy | ||||
| No | (reference) | (reference) | ||
| Yes | 0.24 (0.16–0.36) | <0.001 | 0.32 (0.20–0.50) | <0.001 |
Multivariate Cox regression analysis of time to recurrence (TTR) and overall survival (OS).
HR, hazard ratio; CI, confidential interval; BMI, body mass index; PR, progesterone receptor; pCR, pathological complete response; LVI, lymphovascular invasion; A + T, anthracycline and taxane; A, anthracycline; T, taxane.